(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on a new advertising campaign against Section 306 in S. 1895, the “Lower Health Care Costs Act:”
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug costs for consumers — if enacted, “delinking” would hand a
“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it, Alex Brill, founder and CEO of Matrix Global Advisors (MGA) and former policy director and chief economist for the House
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy benefit companies in Congress, specifically how policies would lead to increased health care costs for consumers, patients, and families, and
Click here to read PCMA’s letter to the Administration’s COVID-19 Task Force. As the Pharmaceutical Care Management Association (PCMA) closely monitors the COVID-19 outbreak, our industry’s priority is that Americans have ready access to the medications that they need in
In case you missed it, PCMA President and CEO JC Scott testified before the U.S. House Education and the Workforce Committee Subcommittee on Health, Employment, Labor, and Pensions. During Scott’s testimony, he highlighted the critical role of pharmacy benefit companies in
©2024 PCMA. All Rights Reserved.
